CURRENT CLINICAL INTERESTS
Hematologic malignancies, benign hematologic disorders, bleeding and thrombotic disorders, therapeutic apheresis and stem cell procurement
CURRENT RESEARCH INTERESTS
Safe and effective
management of patients and donors undergoing marrow harvest and
peripheral blood stem cell mobilization and collection by apheresis
Linenberger is the local principal investigator on a multicenter
study of hematopoietic stem cell donor safety and quality of life,
sponsored by the Center for International Blood and Marrow Transplant
Research. In his role as Medical Director of Cellular
Therapy and Apheresis, Dr. Linenberger supports the activities of the
Cell Processing Core of the Fred Hutchinson Cancer Research Center (FHCRC),
which provides critical instrumentation and technical expertise for
the procurement, characterization and processing of all clinical
cellular components necessary for the treatment of patients
and for correlative research studies. These activities
support the investigational protocols that utilize the Cellular
Processing Facility (a GMP production laboratory) and a research
Linenberger ML, Kindelan J, Bennett RL, Reiner AP,
and Côté HCF: Fibrinogen
Bellingham: A g-chain R275C substitution and a b-promoter polymorphism in a thrombotic
member of an asymptomatic family.
Am. J. Hematol.
Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley
TA, Bennett JM, Berger MS, Leopold LH, Appelbaum FR, and Bernstein ID:
Multidrug resistance phenotype and clinical responses to
gemtuzumab ozogamicin. Blood
Walter RB, Raden BW, Hong TC, Flowers
DA, Bernstein ID, and Linenberger ML. Multidrug resistance
protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute
myeloid leukemia cells. Blood 102:1466-1473, 2003.
and Wittkowski AK. Thromboembolic
complications of malignancy: Part 1.
19: 853-861, 2005.
CD33-Directed therapy with gemtuzumab ozogamicin in acute myeloid
leukemia: progress in understanding cytotoxicity and potential
mechanisms of resistance. Leukemia
and Wittkowski AK. Thromboembolic
complications of malignancy: Part 2.
Management. Oncology 19:1077-1084, 2005.
Catheter-related thrombosis: risks, diagnosis and management. J.
Natl. Compr. Canc. Netw. 4:889-901, 2006.
Shaz BH, Linenberger
ML, Bandarenko N et al. Category IV
indications for therapeutic apheresis-ASFA fourth special issue. J. Clin. Apheresis 22:176-180, 2007.
M, Howson-Jan K, et al.
Acute myeloid leukemia in a healthy hematopoietic stem cell
donor following past exposure to a short course of G-CSF. Leukemia
LD, Baird MF, Bennett CL, Bockenstedt PL, Cataland SR, Fanikos J,
Fogarty PF, Goldhaber SZ, Grover TS, Haire W, Hassoun H, Hutchinson S,
Jahanzeb M, Lee J, Linenberger
ML, Millenson MM, Ortel TL, Salem R, Smith JL, Streiff
MB, Vedantham S; National Comprehensive Cancer Network. Venous
thromboembolic disease. NCCN. Clinical practice guidelines in
oncology. J. Natl. Compr. Canc. Netw. 6:716-53, 2008.
K and Linenberger
M, Chasing clot: thrombophilic states and the
interventionist. J. Vasc. Interv.
Radiol. 20:1403-16 2009.
Linenberger M: Collection
of cellular therapy products by apheresis.
In Cellular Therapy: Principles, Methods and Regulations,
Ellen M Areman and Kathy Loper (eds), AABB Press, 2009.
ZM*, Winters JL, Bandarenko N, Kim HC, Linenberger
ML, Marques MB, Sarode R, Schwartz J, Weinstein R,
Shaz BH; Apheresis Applications Committee of the American Society for
Apheresis. Guidelines on the use of therapeutic apheresis in clinical
practice – evidence-based approach from the Apheresis Applications
Committee of the American Society for Apheresis. J.
Clin. Apheresis 25:83-177, 2010.
Schwartz J, Padmanabhan A, Francis R and Linenberger
M: Mobilization and collection of peripheral blood
hematopoietic progenitor cells. In
Apheresis: Principles and
Practice, 3rd Edition, McLeod BC, Szczepiorkowski ZM,
Weinstein R, Winters JL (eds), Bethesda, MD:
AABB Press, 2010.
Nester T and Linenberger,
M: Therapeutic apheresis: Technical considerations and
indications in critical care. In Irwin and Rippe’s Intensive Care
Medicine 7th Edition, Richard S. Irwin and James M.
Rippe (eds), Wolters Kluwer/Lippincott Williams & Wilkins, 2012.
Khera N, Jinneman J, Storer BE, Heimfeld S, O'Meara MM, Chauncey TR, Lee SJ, Linenberger M. Limiting the Daily Total Nucleated Cell Dose of Cryopreserved Peripheral Blood Stem Cell Products for Autologous Transplantation Improves Infusion-Related Safety with No Adverse Impact on Hematopoietic Engraftment. Biol Blood Marrow Transplant 18:220-28, 2012.
Scott BL, Gooley TA, Sorror ML, Rezvani AR, Linenberger ML, Grim J, Sandmaier BM, Myerson D, Chauncey TR, Storb R, Buxhofer-Ausch V, Radich JP, Appelbaum FR, Deeg HJ. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood 119:2657-64, 2012.
Gopal AK, Karami M, Mayor J, Macebeo M, Linenberger M, Bensinger WI, Holmberg L. The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34+ cells. J Clin Apheresis 27:81-7, 2012.